{
    "elements": [
        {
            "type": "table",
            "sequence_num": 1,
            "data": {
                "num_rows": 15,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "Document Title:"
                    },
                    {
                        "text": "RESEARCH & DEVELOPMENT SERIOUS BREACHES (HOSTED)"
                    },
                    {
                        "text": "Document Reference/Register no:"
                    },
                    {
                        "text": "MEHTSOP043"
                    },
                    {
                        "text": "Version Number:"
                    },
                    {
                        "text": "1.0"
                    },
                    {
                        "text": "Document type: (Policy/ Guideline/ SOP)"
                    },
                    {
                        "text": "SOP"
                    },
                    {
                        "text": "To be followed by: (Target Staff)"
                    },
                    {
                        "text": "All staff"
                    },
                    {
                        "text": "Ratification Issue Date: (Date document is uploaded onto the intranet)"
                    },
                    {
                        "text": "11th December 2019"
                    },
                    {
                        "text": "Review Date:"
                    },
                    {
                        "text": "th10 December 2022"
                    },
                    {
                        "text": "Developed in response to:"
                    },
                    {
                        "text": "Service Development"
                    },
                    {
                        "text": "Contributes to HSC Act 2008 (Regulated Activities) Regulations 2014(Part 3); and CQC Regulations 2009 (Part 4) CQC Fundamental Standards of Quality and Safety:"
                    },
                    {
                        "text": "17"
                    },
                    {
                        "text": "Issuing Division/Directorate:"
                    },
                    {
                        "text": "Research & Development"
                    },
                    {
                        "text": "Author/Contact: (Asset Administrator)"
                    },
                    {
                        "text": "Lauren Perkins R & D Manager"
                    },
                    {
                        "text": "Hospital Sites: (tick appropriate box/es to indicate status of policy review i.e. joint/ independent)"
                    },
                    {
                        "text": "\uf0fcMEHT \u25a1 BTUH \u25a1 SUH"
                    },
                    {
                        "text": "Consultation:"
                    },
                    {
                        "text": "(Refer to page 2)"
                    },
                    {
                        "text": "Approval Group / Committee(s):"
                    },
                    {
                        "text": "Research and Development"
                    },
                    {
                        "text": "Date:"
                    },
                    {
                        "text": "05/07/2019"
                    },
                    {
                        "text": "Professionally Approved by: (Asset Owner)"
                    },
                    {
                        "text": "Tracey Camburn R & D Director, Clinical Lead Nurse"
                    },
                    {
                        "text": "Date:"
                    },
                    {
                        "text": "26/07/2019"
                    },
                    {
                        "text": "Ratification Group(s):"
                    },
                    {
                        "text": "DRAG Chair's Action"
                    },
                    {
                        "text": "Date:"
                    },
                    {
                        "text": "11th December 2019"
                    },
                    {
                        "text": "Executive and Clinical Directors (Communication of minutes from Document Ratification Group"
                    },
                    {
                        "text": "Date: December 2019"
                    },
                    {
                        "text": "Distributio n Method:"
                    },
                    {
                        "text": "Intranet & Website"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 2,
            "data": {
                "num_rows": 13,
                "num_cols": 2,
                "table_items": [
                    {
                        "text": "Consulted With:"
                    },
                    {
                        "text": "Post/ Approval Committee/ Group:"
                    },
                    {
                        "text": "Date:"
                    },
                    {
                        "text": "Jo Wootton"
                    },
                    {
                        "text": "Oncology Research Nurse"
                    },
                    {
                        "text": "02/07/2019 05/07/2019"
                    },
                    {
                        "text": "Carole Bartlett"
                    },
                    {
                        "text": "Primary Care Research Nurse"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 3,
            "data": {
                "num_rows": 1,
                "num_cols": 2,
                "table_items": [
                    {
                        "text": "Related Trust Policies (to be read in conjunction with)"
                    },
                    {
                        "text": "MEHTSOP004 SAEs (Sponsored) MEHTSOP005 Informed Consent MEHTSOP006 SAEs (Hosted) MEHTSOP062 Trial Master File MEHTSOP061 Research Staff Training MEHTSOP004 Role of CI, pharmacy, nuclear medicine and R&D MEHTSOP059 Amendments"
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 4,
            "data": {
                "num_rows": 10,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "Document Review History:"
                    },
                    {
                        "text": "Version No:"
                    },
                    {
                        "text": "Authored/Reviewer:"
                    },
                    {
                        "text": "Summary of amendments/ Record documents superseded by:"
                    },
                    {
                        "text": "Issue Date:"
                    },
                    {
                        "text": "1.0"
                    },
                    {
                        "text": "Lauren Perkins"
                    },
                    {
                        "text": "Newly created"
                    },
                    {
                        "text": "11th December 2019"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 5,
            "data": {
                "is_heading": 1,
                "text": "Contents"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 6,
            "data": {
                "is_heading": 1,
                "prefix": 3.0,
                "text": "Background"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 7,
            "data": {
                "is_heading": 1,
                "prefix": 3.0,
                "text": "Purpose"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 8,
            "data": {
                "is_heading": 1,
                "prefix": 3.0,
                "text": "Applicable to"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 9,
            "data": {
                "is_heading": 1,
                "prefix": 3.0,
                "text": "Responsibilities"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 10,
            "data": {
                "is_heading": 1,
                "prefix": 4.0,
                "text": "Procedure"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 11,
            "data": {
                "is_heading": 1,
                "prefix": 6.0,
                "text": "Related documents"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 12,
            "data": {
                "is_heading": 1,
                "prefix": 6.0,
                "text": "References"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 13,
            "data": {
                "is_heading": 1,
                "prefix": 6.0,
                "text": "Equality Impact Assessment"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 14,
            "data": {
                "is_heading": 0,
                "text": "Appendix 1 \u2013 Definitions"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 15,
            "data": {
                "is_heading": 0,
                "text": "Appendix 2 \u2013 Examples of Serious Breaches Appendix 3 \u2013 Preliminary Equality Analysis"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 16,
            "data": {
                "is_heading": 1,
                "prefix": 1.0,
                "text": "BACKGROUND"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 17,
            "data": {
                "is_heading": 0,
                "prefix": 1.1,
                "text": "This document sets out the procedures to be followed by all Mid Essex Hospital Services NHS Trust (MEHT) staff who are involved in Clinical Trials of Medicinal Products (CTIMPs) and non-CE marked Medical Devices."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 18,
            "data": {
                "is_heading": 0,
                "prefix": 1.2,
                "text": "It provides guidance on how serious breaches of the trial protocol must be identified and managed."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 19,
            "data": {
                "is_heading": 0,
                "prefix": 1.0,
                "text": "The procedures to be followed to ensure compliance with Regulation 29A of the UK Medicines for Human Use (Clinical Trials) Regulations  (Statutory Instrument"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 20,
            "data": {
                "is_heading": 0,
                "text": "2004/1031) as amended by Statutory Instrument 2006/1928, are fully detailed."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 21,
            "data": {
                "is_heading": 1,
                "text": "Notification of serious breaches - 29A."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 22,
            "data": {
                "is_heading": 0,
                "prefix": 1.4,
                "text": "The sponsor of a clinical trial shall notify the licensing authority in writing of any serious breach of:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 23,
            "data": {
                "is_heading": 0,
                "prefix": 1.5,
                "text": "For the purposes of this regulation, a \u201cserious breach\u201d is a breach which is likely to affect, to a significant degree;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 24,
            "data": {
                "is_heading": 0,
                "prefix": 1.6,
                "text": "These stipulations were incorporated into regulation to:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 25,
            "data": {
                "is_heading": 0,
                "prefix": 1.7,
                "text": "Deviations from clinical trial protocols and GCP occur commonly in clinical trials. The majority of these instances are technical deviations that do not result in harm to the trial subjects or significantly affect the scientific value of the reported results of the trial. These cases should be documented e.g. in the case report form (CRF) for the trial or Trial Master File (TMF), in order for appropriate corrective and preventative actions (CAPA) to be taken. In addition, these deviations should be included and considered when the clinical study report is produced, as they may have an impact on the analysis of the data. However, not every deviation from the protocol needs to be reported to the MHRA as a serious breach. The reporting procedures for protocol violation/deviation are usually defined in the clinical trial protocol."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 26,
            "data": {
                "is_heading": 0,
                "prefix": 1.8,
                "text": "The judgement on whether a breach is likely to have a significant impact on the scientific value of the trial depends on a variety of factors including the design of the trial, the type and extent of the data affected by the breach, the overall contribution of the data to key analysis parameters, the impact of excluding the data from the analysis etc."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 27,
            "data": {
                "is_heading": 0,
                "prefix": 1.9,
                "text": "It is the responsibility of the Sponsor to assess the impact of the breach on the scientific value of the trial. Anyone who is unsure whether a breach has occurred can contact the R&D Office to discuss the situation and clarify whether a breach is classed as serious (examples of possible serious breaches can be found in Appendix 2)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 28,
            "data": {
                "is_heading": 1,
                "prefix": 2.0,
                "text": "PURPOSE"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 29,
            "data": {
                "is_heading": 0,
                "text": "\u25cf To outline procedures for identifying a potential serious breach of GCP or protocol violation."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 30,
            "data": {
                "is_heading": 0,
                "text": "\u25cf To describe the process for notification of serious breaches of GCP or the approved trial protocol."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 31,
            "data": {
                "is_heading": 0,
                "text": "\u25cf To ensure appropriate assessments are carried out by relevant parties and fully documented."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 32,
            "data": {
                "is_heading": 0,
                "text": "\u25cf To outline the role of the Research & Development (R&D) in assessing the reported serious breaches and the escalation process."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 33,
            "data": {
                "is_heading": 1,
                "prefix": 3.0,
                "text": "APPLICABLE TO"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 34,
            "data": {
                "is_heading": 0,
                "prefix": 3.1,
                "text": "Any Trust employees involved (including those with an honorary research contract or letter of access) with clinical research including, Chief Investigators (CI), Principal Investigators (PI), Consultants, Clinical Trial Pharmacists, Research Managers, Research Midwives, Statisticians, Research Nurses, Trial Coordinators & Data Managers."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 35,
            "data": {
                "is_heading": 1,
                "prefix": 4.0,
                "text": "RESPONSIBILITIES"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 36,
            "data": {
                "is_heading": 0,
                "prefix": 4.1,
                "text": "All researchers must ensure all possible serious breaches are reported to the PI immediately (within 24 hours) or as stated in the protocol."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 37,
            "data": {
                "is_heading": 0,
                "prefix": 4.2,
                "text": "The PI or delegated individual (DI) of the study shall ensure that the Serious Breach is reported to the Chief Investigator, Sponsor and the R&D Office (within 24 hours)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 38,
            "data": {
                "is_heading": 0,
                "prefix": 4.3,
                "text": "For any possible Serious Breaches identified by the R&D Office, R&D shall ensure that they are assessed immediately and appropriate recommendations are made to the PI regarding further management of the breach and notification to patients."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 39,
            "data": {
                "is_heading": 0,
                "prefix": 4.4,
                "text": "For any possible Serious Breaches reported to the R&D Office, R&D shall ensure that they are assessed for their impact on the Trust and patient safety and if required shall provide appropriate recommendations on behalf of the Trust."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 40,
            "data": {
                "is_heading": 1,
                "prefix": 5.0,
                "text": "PROCEDURE"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 41,
            "data": {
                "is_heading": 1,
                "prefix": 5.1,
                "text": "Procedure for possible Serious Breaches of GCP identified by Sponsor"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 42,
            "data": {
                "is_heading": 1,
                "text": "A possible serious breach of GCP has been identified for a hosted clinical trial by the Sponsor"
            }
        },
        {
            "type": "image",
            "sequence_num": 43,
            "data": {
                "url": "MEHTSOP043 Serious Breaches (hosted) 1.0.001.png"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 44,
            "data": {
                "is_heading": 0,
                "text": "PI informed of possible breach by the Sponsor as stated in the protocol/clinical trial"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 45,
            "data": {
                "is_heading": 0,
                "text": "agreement"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 46,
            "data": {
                "is_heading": 0,
                "text": "Wi"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 47,
            "data": {
                "is_heading": 0,
                "text": "thi"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 48,
            "data": {
                "is_heading": 0,
                "text": "n"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 49,
            "data": {
                "is_heading": 0,
                "prefix": 24.0,
                "text": ""
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 50,
            "data": {
                "is_heading": 0,
                "text": "ho"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 51,
            "data": {
                "is_heading": 0,
                "text": "ur PI forwards a copy of the  PI reports serious breach as a Serious  s"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 52,
            "data": {
                "is_heading": 0,
                "text": "Sponsor's report to the R&D  Untoward Incidence to the Trust in"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 53,
            "data": {
                "is_heading": 0,
                "text": "Office immediately  accordance with the Adverse Incident Policy"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 54,
            "data": {
                "is_heading": 0,
                "text": "Wi R&D assesses serious breach for  thi"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 55,
            "data": {
                "is_heading": 0,
                "prefix": 24.0,
                "text": "ismafpaetcy ant on Td ifr neust acesndsar pay mtientak es  n appropriate recommendations"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 56,
            "data": {
                "is_heading": 0,
                "text": "(CAPA) ho"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 57,
            "data": {
                "is_heading": 0,
                "text": "ur"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 58,
            "data": {
                "is_heading": 0,
                "text": "s"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 59,
            "data": {
                "is_heading": 1,
                "prefix": 5.2,
                "text": "Procedure for possible Serious Breaches of GCP identified by Research Team"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 60,
            "data": {
                "is_heading": 1,
                "text": "A possible Serious Breach of GCP has been identified for hosted clinical trial by the Research Team Within 24 hours of identification"
            }
        },
        {
            "type": "image",
            "sequence_num": 61,
            "data": {
                "url": "MEHTSOP043 Serious Breaches (hosted) 1.0.002.png"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 62,
            "data": {
                "is_heading": 0,
                "text": "PI informed immediately"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 63,
            "data": {
                "is_heading": 1,
                "text": "Within 24 hours of identification"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 64,
            "data": {
                "is_heading": 0,
                "text": "The Principal Investigator or delegated individual of the study shall ensure that the Serious Breach is reported as required to the Sponsor (See protocol and clinical trial agreement)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 65,
            "data": {
                "is_heading": 0,
                "text": "If breach decided as serious then the Sponsor will  If breach decided not to be serious then report to the appropriate regulatory authorities and  Sponsor will inform PI"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 66,
            "data": {
                "is_heading": 0,
                "text": "will inform PI of necessary actions (CAPA)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 67,
            "data": {
                "is_heading": 0,
                "text": "Research Team to keep all"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 68,
            "data": {
                "is_heading": 0,
                "text": "PI reports Serious Breach as  PI forwards a copy of the  documentation regarding the potential a Serious Untoward Incidence  Sponsor's report to the R&D  breach in the"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 69,
            "data": {
                "is_heading": 0,
                "text": "to the Trust in accordance  Office immediately  Investigator site file"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 70,
            "data": {
                "is_heading": 1,
                "text": "with the Incident Policy  (Within 24 hours)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 71,
            "data": {
                "is_heading": 1,
                "text": "Within 24 hours of notification"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 72,
            "data": {
                "is_heading": 0,
                "text": "R&D assesses Serious Breach for impact on Trust and patient safety and if necessary makes appropriate recommendations"
            }
        },
        {
            "type": "image",
            "sequence_num": 73,
            "data": {
                "url": "MEHTSOP043 Serious Breaches (hosted) 1.0.003.png"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 74,
            "data": {
                "is_heading": 1,
                "prefix": 5.3,
                "text": "Procedure for possible Serious breaches of GCP identified by R&D audit"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 75,
            "data": {
                "is_heading": 0,
                "text": "R&D Audit identifies a possible serious breach of GCP"
            }
        },
        {
            "type": "image",
            "sequence_num": 76,
            "data": {
                "url": "MEHTSOP043 Serious Breaches (hosted) 1.0.004.png"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 77,
            "data": {
                "is_heading": 0,
                "text": "If considered serious by R&D  If not considered serious by R&D"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 78,
            "data": {
                "is_heading": 0,
                "text": "Research team informed of possible  Research team informed R&D serious breach and R&D  recommendations. The research recommendations on behalf of the  team must inform the Sponsor of the Trust regarding patient safety audit findings"
            }
        },
        {
            "type": "image",
            "sequence_num": 79,
            "data": {
                "url": "MEHTSOP043 Serious Breaches (hosted) 1.0.005.png"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 80,
            "data": {
                "is_heading": 1,
                "text": "The PI of the study shall ensure that the possible serious breach is reported as required to the sponsor (protocol and clinical trial agreement) within 24 hours"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 81,
            "data": {
                "is_heading": 0,
                "text": "If the breach is considered serious,"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 82,
            "data": {
                "is_heading": 0,
                "text": "the Sponsor will report to the  If breach considered not being regulatory authorities and will inform  serious, Sponsor will inform the PI"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 83,
            "data": {
                "is_heading": 0,
                "text": "the PI of necessary actions (CAPA)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 84,
            "data": {
                "is_heading": 0,
                "text": "PI reports serious  Research team keep  PI forwards a copy of the PI forwards a copy  breach as a Serious  all documentation  Sponsors report to R&D of the Sponsor's  Untoward Incidence  regarding breach in  immediately"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 85,
            "data": {
                "is_heading": 0,
                "text": "report to R&D  to the Trust via  the investigator file"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 86,
            "data": {
                "is_heading": 1,
                "text": "immediately (within  accordance with the"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 87,
            "data": {
                "is_heading": 1,
                "prefix": 24.0,
                "text": "hours)  Trust's Incidence  R&D assesses Sponsor's Policy  reply and determines if"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 88,
            "data": {
                "is_heading": 0,
                "text": "should be classified and"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 89,
            "data": {
                "is_heading": 0,
                "text": "Serious Untoward Incident"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 90,
            "data": {
                "is_heading": 0,
                "text": "R&D assesses"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 91,
            "data": {
                "is_heading": 0,
                "text": "Sponsor's reply and"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 92,
            "data": {
                "is_heading": 0,
                "text": "determines if this meets"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 93,
            "data": {
                "is_heading": 0,
                "text": "PI reports serious breach as their requirements on  Serious Untoward Incident to"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 94,
            "data": {
                "is_heading": 0,
                "text": "behalf of the Trust to  the Trust in accordance with ensure patient safety  Rthe&D fir oraswsardsessm a enct aopndy of  the Trust's Incident Policy"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 95,
            "data": {
                "is_heading": 0,
                "text": "recommendation to the"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 96,
            "data": {
                "is_heading": 0,
                "text": "Sponsor (where applicable)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 97,
            "data": {
                "is_heading": 1,
                "prefix": 5.4,
                "text": "Corrective and Preventative Action (CAPA Cycle)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 98,
            "data": {
                "is_heading": 1,
                "text": "1) IDENTIFY & ASSESS"
            }
        },
        {
            "type": "image",
            "sequence_num": 99,
            "data": {
                "url": "MEHTSOP043 Serious Breaches (hosted) 1.0.006.png"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 100,
            "data": {
                "is_heading": 0,
                "text": "Identify the problem"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 101,
            "data": {
                "is_heading": 0,
                "text": "Assess the Impact"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 102,
            "data": {
                "is_heading": 0,
                "text": "Notification to the relevant individuals"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 103,
            "data": {
                "is_heading": 1,
                "text": "4) VERIFY EFFECTIVENESS  2) INVESTIGATE, ROOT CAUSE ANALYSIS, ACTION PLAN"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 104,
            "data": {
                "is_heading": 0,
                "text": "Measure to ensure the problem has"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 105,
            "data": {
                "is_heading": 0,
                "text": "been resolved (Corrective Action) Complete the investigation"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 106,
            "data": {
                "is_heading": 0,
                "text": "Determine the root cause"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 107,
            "data": {
                "is_heading": 0,
                "text": "Monitor to ensure it is not recurring  Propose Corrective & Preventative (Preventative Action) Actions (CAPA)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 108,
            "data": {
                "is_heading": 0,
                "text": "Plan effectiveness"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 109,
            "data": {
                "is_heading": 1,
                "text": "3) REVIEW AND APPROVE PLAN, IMPLEMENT ACTIONS"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 110,
            "data": {
                "is_heading": 0,
                "text": "Implement agreed CAPA"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 111,
            "data": {
                "is_heading": 0,
                "text": "Verify actions completed"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 112,
            "data": {
                "is_heading": 0,
                "text": "Notification to the relevant individuals"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 113,
            "data": {
                "is_heading": 1,
                "prefix": 5.5,
                "text": "Provision of additional information to the Sponsor"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 114,
            "data": {
                "is_heading": 0,
                "text": "5.5.1 Once the initial notification has been submitted to the Sponsor, the PI and R&D Office will review the breach in full to identify the extent of the breach and continue to update the Sponsor with new information."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 115,
            "data": {
                "is_heading": 0,
                "text": "5.5.2 The PI and R&D Office will also facilitate any related Sponsor audits and MHRA inspections related to the breach."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 116,
            "data": {
                "is_heading": 1,
                "prefix": 5.6,
                "text": "Other Reporting Requirements (e.g. Reporting to the Trust Risk Management Group) and Implementing Corrective and Preventative Action (CAPA)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 117,
            "data": {
                "is_heading": 0,
                "text": "5.6.1 Any possible serious breach that occurs may also require reporting to the Trust's risk management team in accordance with the Trust Policy. The R&D Office shall make recommendations to the PI/study team about where further reporting requirements apply."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 118,
            "data": {
                "is_heading": 0,
                "text": "5.6.2 The breach may also require reporting to the ethics committee if it is in breach of the ethical conditions of study approval."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 119,
            "data": {
                "is_heading": 0,
                "text": "5.6.3 Following the initial assessment of seriousness and impact of the GCP breach, the R&D Office may carry out a full audit of the trial and general trial management systems and procedures. The R&D Office will implement any relevant systems or operational changes as required."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 120,
            "data": {
                "is_heading": 1,
                "prefix": 6.0,
                "text": "RELATED DOCUMENTS"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 121,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Standard Operating Procedures Working Group Terms of Reference"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 122,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Membership of Standard Operating Procedures Working Group"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 123,
            "data": {
                "is_heading": 1,
                "text": "\u25cf Statutory Instrument 2004/1031:  The Medicines for Human Use (Clinical Trials) Regulations 2004"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 124,
            "data": {
                "is_heading": 1,
                "text": "\u25cf Statutory Instrument 2006/1928:  The Medicines for Human Use (Clinical Trials) Amendment Regulations 2006"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 125,
            "data": {
                "is_heading": 0,
                "text": "\u25cf Guidance for the Notification of Serious Breaches of GCP or the Trial Protocol, MHRA"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 126,
            "data": {
                "is_heading": 1,
                "prefix": 7.0,
                "text": "REFERENCES"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 127,
            "data": {
                "is_heading": 0,
                "text": "The Medicines for Human Use (Clinical Trials) (2004) regulations"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 128,
            "data": {
                "is_heading": 1,
                "prefix": 8.0,
                "text": "EQUALITY IMPACT ASSESSMENT"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 129,
            "data": {
                "is_heading": 0,
                "prefix": 8.1,
                "text": "Mid Essex Hospital Services NHS Trust is committed to the provision of a service that is fair, accessible and meets the needs of all individuals. (Refer to Appendix 3)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 130,
            "data": {
                "is_heading": 1,
                "text": "Appendix 1: Definitions"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 131,
            "data": {
                "is_heading": 1,
                "text": "Adverse Event (AE) -  Any untoward medical occurrence in a subject to whom a medicinal product has been administered, including occurrences which are not necessarily caused by or related to that product"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 132,
            "data": {
                "is_heading": 1,
                "text": "Case Record Form (CRF) - A printed, optical, or electronic document designed to record all of the protocol required information to be reported to the sponsor on each trial subject\u201d."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 133,
            "data": {
                "is_heading": 1,
                "text": "Chief Investigator (CI) -  The person who takes overall responsibility for the design, conduct and reporting of a study if it is at one site; or if the study involves researchers at more than one site, the person who takes primary responsibility for the design conduct and reporting of the study whether or not that person is an Investigator at any particular site."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 134,
            "data": {
                "is_heading": 1,
                "text": "Clinical Trial - Any investigation in human subjects, other than a non-interventional trial intended to discover or verify the clinical, pharmacological or other pharmacodynamic effects of one or more medicinal product or to identify any adverse reactions to one or more such products and to study absorption, distribution metabolism and excretion in one of more such products with the object of ascertaining the safety or efficacy of those products."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 135,
            "data": {
                "is_heading": 1,
                "text": "Clinical Trial Authorisation (CTA) -  Regulatory approval issued by a Competent Authority to conduct a clinical trial within a Member State."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 136,
            "data": {
                "is_heading": 0,
                "text": "Re such products and to study absorption, distribution metabolism and excretion in one of more such products with the object of ascertaining the safety or efficacy of those products."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 137,
            "data": {
                "is_heading": 1,
                "text": "Clinical Trial of an Investigational Medicinal Product (CTIMP) - This is defined as any Clinical Research Study which intends to generate new information about the safety or efficacy of a Medicinal Product."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 138,
            "data": {
                "is_heading": 1,
                "text": "Delegated Individual (DI) - An individual delegated by the PI to carry out their tasks."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 139,
            "data": {
                "is_heading": 1,
                "text": "Good Clinical Practice (GCP) - The principles of Good Clinical Practice in Clinical Trials as set down in Articles 2-5 of the GCP Directive and implemented in the UK by Schedule 1 of the Medicines for Human Use (Clinical Trials) Regulations 2004 (S.I.2004/1031) as amended by S.I. 2006/19281."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 140,
            "data": {
                "is_heading": 0,
                "text": "Good Clinical Practice is a set of internationally recognised ethical and scientific quality requirements which must be observed for designing, conducting, recording and reporting clinical trials that involve the participation of human subjects."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 141,
            "data": {
                "is_heading": 1,
                "text": "Honorary research contracts (HRCs) - HRCs are required for researchers who are not employees of the NHS and whose activities could have a foreseeable and direct impact on patient care."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 142,
            "data": {
                "is_heading": 1,
                "text": "International Conference on Harmonisation (ICH) -  International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use is a joint initiative involving both regulators and research-based industry focusing on the technical requirements for medicinal products containing new drugs."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 143,
            "data": {
                "is_heading": 1,
                "text": "Investigational Medicinal Products (IMP) -  A pharmaceutical form of an active substance or placebo being tested, or used as a reference in a clinical trial. This includes a medicinal product which has a marketing authorisation but is, for the purposes of the trial -"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 144,
            "data": {
                "is_heading": 0,
                "text": "(a) Used or assembled (formulated or packaged) in a way different from the form of the product authorised under the authorisation,"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 145,
            "data": {
                "is_heading": 0,
                "text": "(b) Used for an indication not included in the summary of product characteristics under the authorisation for that product, or"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 146,
            "data": {
                "is_heading": 0,
                "text": "(c) Used to gain further information about the form of that product as authorised under the authorisation"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 147,
            "data": {
                "is_heading": 1,
                "text": "Letter of Access - Letters of access enable NHS employees or staff with an honorary clinical contract (e.g. clinical academics) with one NHS organisation to conduct research in another NHS organisation."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 148,
            "data": {
                "is_heading": 1,
                "text": "Principal Investigator (PI) - The leader responsible for a team of individuals conducting a study at a (participating) site."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 149,
            "data": {
                "is_heading": 1,
                "text": "Serious Adverse Event (SAE) or Serious Adverse Reaction (SAR)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 150,
            "data": {
                "is_heading": 0,
                "text": "Any untoward medical occurrence or effect that at any dose results in:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 151,
            "data": {
                "is_heading": 0,
                "text": "\u00b7 Death"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 152,
            "data": {
                "is_heading": 0,
                "text": "\u00b7 Is life-threatening*"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 153,
            "data": {
                "is_heading": 0,
                "text": "\u00b7 Requires hospitalisation or prolongation of existing hospitalisation"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 154,
            "data": {
                "is_heading": 0,
                "text": "\u00b7 Results in persistent or significant disability or incapacity"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 155,
            "data": {
                "is_heading": 0,
                "text": "\u00b7 Is a congenital anomaly or birth defect"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 156,
            "data": {
                "is_heading": 0,
                "text": "\u00b7 Is an important medical event"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 157,
            "data": {
                "is_heading": 0,
                "text": "* \u201clife-threatening\u201d refers to an event in which the patient was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 158,
            "data": {
                "is_heading": 1,
                "text": "Statutory Instrument (SI)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 159,
            "data": {
                "is_heading": 0,
                "text": "Legal means of implementation of EU Clinical Trials Directive into UK law. SI 1031 (2004), subsequently amended by SI 1928 (2006), SI 2984 (2006), SI 941 (2008) and SI 1184 (2009)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 160,
            "data": {
                "is_heading": 1,
                "text": "The Medicines & Healthcare products Regulatory Agency (MHRA) - The government agency which is responsible for ensuring that medicines and medical devices work, and are acceptably safe."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 161,
            "data": {
                "is_heading": 0,
                "text": "The MHRA can also be defined as:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 162,
            "data": {
                "is_heading": 0,
                "text": "MHRA (Medicines) is the competent authority for the UK in relation to the EU Directive and the Clinical Trials Regulations. MHRA (Devices) is the competent authority for the UK in relation to the Medical Devices Regulations 2002."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 163,
            "data": {
                "is_heading": 1,
                "text": "The Regulations"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 164,
            "data": {
                "is_heading": 0,
                "prefix": 1928.0,
                "text": "Medicines for Human Use (Clinical Trial) Regulations 2004 transposed the EU Clinical Trials Directive into UK legislation, as Statutory Instrument 2004 no 1031. This became effective on the 1st May 2004. An amendment to implement Directive 2005/28/EC was made to the Regulations as Statutory Instrument 2006 no"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 165,
            "data": {
                "is_heading": 1,
                "text": "Trial Master File"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 166,
            "data": {
                "is_heading": 0,
                "text": "The Trial Master File (TMF) will be held at the principal site by the sponsor, Chief Investigator or at the co-ordinating Centre. The TMF should contain all essential documents defined as documents which individually and collectively permit evaluation of the conduct of a trial and the quality of the data produced. A Trial Master File should be set up at the beginning of a trial and maintained up-to-date throughout the trial until trial conclusion."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 167,
            "data": {
                "is_heading": 0,
                "text": "For trials currently running, it is recommended that Section 8 of the ICH-GCP Guideline is followed as guidance in order to meet statutory requirements. However, some of the documents listed may not be available or applicable in many non-commercial trials. The appropriate documentation will vary according to the trial and sponsor requirements."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 168,
            "data": {
                "is_heading": 1,
                "text": "Appendix 2: Examples of serious breaches"
            }
        },
        {
            "type": "table",
            "sequence_num": 169,
            "data": {
                "num_rows": 3,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "Category:"
                    },
                    {
                        "text": "Issue:"
                    },
                    {
                        "text": "Would MHRA have expected this case to be notified?"
                    },
                    {
                        "text": "IMP"
                    },
                    {
                        "text": "Dosing errors reported: A subject was dosed with the incorrect IMP administered via the incorrect route (the IMP used was from a completely different clinical trial to the one the subject was recruited to A subject was dosed with IMP from the incorrect treatment arm. In addition, some months later, the subjects in an entire cohort were incorrectly dosed with IMP three times daily when they should have been dosed once daily One subject was administered additional doses of IMP. The subject was given instructions to take higher doses of IMP than what was stipulated in the protocol. The subject experienced a severe adverse event as a result A subject took IMP that had expired two days ago. The IMP was stable and the subject did not experience any adverse events and this issue was not likely to affect the data credibility of the trial Due to an interactive response technologies (IRT) malfunction 50% of subjects assigned to one arm were unblinded in a blinded trial, furthermore this information was submitted to all trial staff at all investigator sites participating in the trial"
                    },
                    {
                        "text": "Yes, there was significant potential to impact the safety or the rights of trial subjects Yes, There was impact on the safety or physical or mental integrity of trial subjects or on the scientific value of the trial. This issue was systematic and persistence leading to a breach of the Regulation and the trial protocol. The issue persisted despite the implementation of a corrective and preventative action plan Yes, there was impact on the safety of trial subjects and on the scientific value of the trial No, there was no impact on the safety or physical or mental integrity of the trial subject or on the scientific value of the trial. In addition, the assessment of the breach identified this as a single episode and a detailed corrective and preventative action plan was implemented Yes, this could potentially affect the safety of trial subjects, and this was a systematic issue. It also impacts the robustness and reliability of the data generated"
                    },
                    {
                        "text": "Temperature monitoring"
                    },
                    {
                        "text": "IMP temperature excursions reported"
                    },
                    {
                        "text": "Yes, if the situation was not managed and subjects were dosed with IMP assessed as unstable. which resulted in harm/potential harm of subjects. No, if the excursions had been managed appropriately e.g. IMP was moved to alternative location/quarantined as necessary"
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 170,
            "data": {
                "num_rows": 6,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "and an assessment (by qualified personnel) illustrated that there was no impact on subject safety and data integrity, and stability data showed it was stable."
                    },
                    {
                        "text": "IRT issues"
                    },
                    {
                        "text": "Multiple issues with the IRT system across several clinical trials leading to the dispensing of expired IMP and a shortage of IMP at investigator sites in time of subject visits"
                    },
                    {
                        "text": "Yes, there was impact on the safety of trial subjects ad this issue persisted leading to a constant breach of the Regulation or the trial protocol, despite implementation of a corrective and preventative action plan"
                    },
                    {
                        "text": "Potential Fraud"
                    },
                    {
                        "text": "On two separate occasions the sponsor identified issues with the same organisation. First with consenting and then with potential irregularities in recruitment and consenting. However, there was not unequivocal evidence of fraud at the time of reporting. One of the studies involved paediatric subjects"
                    },
                    {
                        "text": "Yes, this subsequently led to enforcement action against the organisation in question"
                    },
                    {
                        "text": "Source Data"
                    },
                    {
                        "text": "Concerns were raised during monitoring visits about changes to source data for a number of subjects in a trial, which subsequently made subjects eligible with no explanation in the subject notes. An audit was carried out by the sponsor and other changes to source data were noted without explanation, potential impacting on data integrity. Follow-up reports confirmed the sponsor concerns over consenting and data changes made to source without an adequate written explanation"
                    },
                    {
                        "text": "Yes, and this needs to be reported when the concerns were raised. Note: not all information was provided in the original notification, the sponsor provided follow up updates"
                    },
                    {
                        "text": "Emergency unbinding"
                    },
                    {
                        "text": "A clinical trial subject attended the hospital emergency department, that attempted to contact the hospital (using the phone number listed on the emergency card issued to the subject) in order to break the unblinding code. Pharmacy was unable to code break in a timely manner, as a result the subject withdrew from the clinical trial feeling unhappy that the pharmacy was not available in an emergency situation"
                    },
                    {
                        "text": "Yes, as this had significant potential to harm the subject if unblinding would have affected the course of the treatment"
                    },
                    {
                        "text": "Sample processing"
                    },
                    {
                        "text": "A cohort had invalid blood samples as they were processed incorrectly. As a result one of the secondary endpoints could not be met. Therefore, a substantial modification was required to recruit more subjects to meet the endpoint"
                    },
                    {
                        "text": "Yes, subjects were dosed unnecessarily as a result of this error"
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 171,
            "data": {
                "num_rows": 2,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "Protocol compliance"
                    },
                    {
                        "text": "Subject safety was compromised because repeat electrocardiograms (ECGs) were not performed, as required by the protocol. The ECGs were required as part of the safety monitoring due to the pharmacology of the IMP. Also, there was inadequate quality control (QC) of the interim safety reports used for dose escalation which has potential for stopping criteria to be missed if adverse events (AEs) were not transcribed from the source to the safety report. Investigator site failed to reduce or stop trial medication, in response to certain laboratory parameters, as required by the protocol. This occurred with several subjects over a one year period, despite identification by the monitor of the first two occasions. Minor visit date deviation. A common deviation in clinical trials. According to the protocol, a brain CT scan should be performed in the selection visit to exclude brain metastasis (exclusion criteria). The site used a previous version of the protocol where the CT scan wasn't required so 6 patients out of 10 were included without brain CT"
                    },
                    {
                        "text": "Yes Yes, subjects were exposed to an increased risk of thrombosis No, a minor protocol deviation, which does not meet the criteria for notification Yes, if this had an impact on patient safety"
                    },
                    {
                        "text": "SAE reporting"
                    },
                    {
                        "text": "The investigator failed to report a single serious adverse event (SAE) as defined in the protocol (re-training provided) The investigator was not clear on the reporting requirements for the trial and was incorrectly classifying events as expected, as they were common events seen with that particular disease The investigator was not documenting all the AEs associated with the trial"
                    },
                    {
                        "text": "No, if this did not result in other trial subjects being put at risk, and if it was not a systematic or persistent problem. In some circumstances, failure to report a SUSAR could have significant impact on trial subjects. Sufficient information and context should be provided for the impact to be assessed adequately Yes, incorrect classification of seriousness criteria, therefore SAEs incorrectly classifies as AEs or under-reporting of large numbers of SUSARs Yes, depending on the type of trial,"
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 172,
            "data": {
                "num_rows": 5,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "for example inadequate safety reporting on dose escalation studies may impact on the decision to escalate to the next dose level"
                    },
                    {
                        "text": "Consent"
                    },
                    {
                        "text": "Patient information leaflet and informed consent updated, but at one trial site this was not relayed to the patients until approximately 2-3 months after approval. More information on the potential consequences of the delay should have been provided."
                    },
                    {
                        "text": "No, if this was not a systematic or persistent problem and if no harm to trial subjects resulted from the delay Yes, if there was a significant impact on the integrity of trial subjects (e.g. there was key safety information not relayed to subjects in a timely manner"
                    },
                    {
                        "text": "Access to data"
                    },
                    {
                        "text": "The investigator would not allow any party access to the patient's notes Loss of data due for example to servers' breakdown"
                    },
                    {
                        "text": "Yes, the data therefore could not be verified. The protocol would usually contain a clause to state that Sponsor representative and Regulatory Authorities will have access to the data, and this is also reflected in the informed consent Yes, clinical trial sponsors and vendor should have agreements in place addressing business continuity and ensuring that clinical trials data are retrievable at any point in time"
                    },
                    {
                        "text": "Randomisation/ stratification errors"
                    },
                    {
                        "text": "Patients incorrectly randomised/stratified according to the protocol"
                    },
                    {
                        "text": "Yes, as this will be likely to have a significant impact on the data"
                    },
                    {
                        "text": "DSMB/DMC"
                    },
                    {
                        "text": "The Data and Safety Monitoring Board (DSMB)/Data Monitoring Committees (DMC), which should be implemented according to the protocol and the clinical trial authorisation in a blinded trial, has in fact not been implemented"
                    },
                    {
                        "text": "Yes, the missing implementation of the DSMB/DMC has significant potential to impact the safety of trial subjects"
                    }
                ]
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 173,
            "data": {
                "is_heading": 0,
                "prefix": 1.0,
                "text": ""
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 174,
            "data": {
                "is_heading": 1,
                "text": "Appendix 3: Preliminary Equality Analysis"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 175,
            "data": {
                "is_heading": 1,
                "text": "This assessment relates to: Research & Development Serious Breaches (hosted) / MEHTSOP043"
            }
        },
        {
            "type": "table",
            "sequence_num": 176,
            "data": {
                "num_rows": 9,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "A change in a service to patients"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "A change to an existing policy"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "A change to the way staff work"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "A new policy"
                    },
                    {
                        "text": "X"
                    },
                    {
                        "text": "Something else (please give details)"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "Questions"
                    },
                    {
                        "text": "Answers"
                    },
                    {
                        "text": "What are you proposing to change?"
                    },
                    {
                        "text": "New SOP"
                    },
                    {
                        "text": "Why are you making this change? (What will the change achieve?)"
                    },
                    {
                        "text": "Review"
                    },
                    {
                        "text": "Who benefits from this change and how?"
                    },
                    {
                        "text": "Patients and clinicians"
                    },
                    {
                        "text": "Is anyone likely to suffer any negative impact as a result of this change? If no, please record reasons here and sign and date this assessment. If yes, please complete a full EIA."
                    },
                    {
                        "text": "No"
                    },
                    {
                        "text": "a) Will you be undertaking any consultation as part of this change? b) If so, with whom?"
                    },
                    {
                        "text": "Refer to pages 1 and 2"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 177,
            "data": {
                "is_heading": 1,
                "text": "Preliminary analysis completed by:"
            }
        },
        {
            "type": "table",
            "sequence_num": 178,
            "data": {
                "num_rows": 1,
                "num_cols": 6,
                "table_items": [
                    {
                        "text": "Name"
                    },
                    {
                        "text": "Lauren Perkins"
                    },
                    {
                        "text": "Job Title"
                    },
                    {
                        "text": "Research & Development Manager"
                    },
                    {
                        "text": "Date"
                    },
                    {
                        "text": "July 2019"
                    }
                ]
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 179,
            "data": {
                "is_heading": 0,
                "prefix": 18.0,
                "text": ""
            }
        }
    ]
}